Clinical Trial Update: Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study is evaluating PYX-201 in combination with pembrolizumab for advanced solid tumors; the trial is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• PYX-201
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Pyxis Oncology, Inc | Conditions: Advanced Solid Tumours | Phase 1, Phase 2 | Status: RECRUITING